AC
PPH icon

AlphaCore Capital’s VanEck Pharmaceutical ETF PPH Stock Holding History

AlphaCore Capital’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.5K Hold
298
– – ﹤0.01% 1326
2026
Q1 		$30.9K Hold
298
– – ﹤0.01% 1052
2025
Q4 		$30.7K Buy
+298
New +$29K ﹤0.01% 1223

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

AlphaCore Capital's PPH Position: Q2 2026 in Review

AlphaCore Capital held its VanEck Pharmaceutical ETF (PPH) position steady in Q2 2026 at 298 shares worth $32.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1326.

AlphaCore Capital first reported a position in PPH in Q4 2025 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

  • AlphaCore Capital held 298 shares of VanEck Pharmaceutical ETF worth $32.5K as of Q2 2026.
  • AlphaCore Capital left its VanEck Pharmaceutical ETF share count unchanged in Q2 2026.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of AlphaCore Capital's portfolio in Q2 2026, its #1326 holding.
  • AlphaCore Capital first reported a position in VanEck Pharmaceutical ETF in Q4 2025 and has held it in 3 quarters since.
  • 148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.